Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database

被引:28
|
作者
Shu, Yamin [1 ]
Zhang, Qilin [2 ]
He, Xucheng [3 ]
Liu, Yanxin [4 ]
Wu, Pan [5 ]
Chen, Li [6 ,7 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Pharm, Tongji Med Coll, Wuhan, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Dept Pharm, Tongji Med Coll, Wuhan, Peoples R China
[3] Pengzhou Second Peoples Hosp, Dept Pharm, Pengzhou, Peoples R China
[4] Pengzhou Peoples Hosp, Dept Pharm, Pengzhou, Peoples R China
[5] Chengfei Hosp, Dept Pharm, Chengdu, Peoples R China
[6] Sichuan Univ, West China Univ Hosp 2, Dept Pharm, Chengdu, Peoples R China
[7] Sichuan Univ, West China Univ Hosp 2, Evidence Based Pharm Ctr, Chengdu, Peoples R China
基金
中国国家自然科学基金;
关键词
data mining; FAERS; fluoroquinolones; pharmacovigilance; tendonitis; tendon rupture; RISK; LEVOFLOXACIN; TENDINOPATHY; CIPROFLOXACIN; MOXIFLOXACIN;
D O I
10.3389/fphar.2022.990241
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The objective of this study was to scientifically and systematically explore the association between fluoroquinolones (ciprofloxacin, levofloxacin, and moxifloxacin) and tendonitis and tendon rupture through the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods: Disproportionality analysis was used to quantify the signals of fluoroquinolone-associated suspected tendonitis and tendon rupture based on the FAERS data from January 2016 to March 2021. Clinical characteristics, the onset time, oral and intravenous administrations, and the serious outcomes of fluoroquinolone-associated tendonitis and tendon rupture were further analyzed. Results: Out of 35,667 fluoroquinolone-associated adverse events recorded in the FAERS database during the study period, 1,771 tendonitis and 1,018 tendon ruptures induced by fluoroquinolones as the suspected drug were analyzed, with a median age of 49.88-63.87 years. All three fluoroquinolones detected positive signals of tendonitis and tendon rupture in the four methods. Ciprofloxacin had the strongest statistical association with tendonitis with the highest positive signal values (ROR 98.50, PRR 93.25, IC 6.15, and EBGM 76.80), while levofloxacin showed the strongest statistical association with tendon rupture (ROR 76.38, PRR 73.75, IC 5.84, and EBGM 63.89). Compared with ciprofloxacin and levofloxacin, moxifloxacin was relatively weakly associated with tendonitis and tendon rupture. Oral fluoroquinolone-induced tendonitis and tendon rupture had a stronger signal strength than intravenous administration. The majority of fluroquinolone-related suspected tendonitis and tendon rupture tended to occur within a few days or one month. As for the disability rate of tendonitis, ciprofloxacin counted the highest (n = 461, 50.94%), with moxifloxacin the lowest (n = 20, 29.41%). Conclusion: Fluoroquinolone-induced tendonitis and tendon rupture tended to occur early and might result in serious outcomes. Our study provided valuable references for early identification of the risk of fluoroquinolone-induced tendonitis and tendon rupture.
引用
收藏
页数:10
相关论文
共 14 条
  • [1] SLEEP APNEA ASSOCIATED WITH TICAGRELOR- A PHARMACOVIGILANCE ANALYSIS FROM 2012-2022 FAERS DATABASE
    Hafez, Nada
    Babayale, Omofolarin
    Faisaluddin, Mohammed
    Ahmed, Asmaa
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 1133 - 1133
  • [2] Anti-seizure medications-associated bladder and urethral symptoms: a pharmacovigilance analysis based on the FAERS database
    Li, Yanyan
    Wu, Zhanshen
    Zhao, Yang
    Shi, Lei
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [3] KETAMINE-ASSOCIATED ADVERSE EVENTS: AN ANALYSIS OF THE FAERS DATABASE FROM 2012-2021
    Alamri, K.
    Guo, J. J.
    VALUE IN HEALTH, 2024, 27 (06) : S368 - S368
  • [4] Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials
    Chen, Wei
    Xie, Jiyi
    Gao, Chen
    Zhang, Cong
    Fu, Zhiwen
    Shi, Chen
    GYNECOLOGIC ONCOLOGY, 2024, 182 : 108 - 114
  • [5] Vascular Events Associated With Cisplatin Based Combination Therapy: An Analysis From Faers Database
    Mann, Chitsimann
    Patel, Brijesh
    Malla, Midhun
    Almubarak, Mohammad
    Fang, Wei
    CIRCULATION, 2022, 146
  • [6] Severe cutaneous adverse reactions associated with antifungal agents: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) database
    Shan, Huifang
    Wei, Chunyan
    Zhang, Jingyi
    Wu, Bin
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [7] Reproductive Toxicity Induced by Serotonin-Norepinephrine Reuptake Inhibitors: A Pharmacovigilance Analysis From 2004 to 2023 Based on the FAERS Database
    Xi, Yujia
    Bao, Zhuocheng
    Guo, Qiang
    Wang, Jingqi
    Jing, Zhinan
    Di, Jingkai
    Yang, Ke
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (12)
  • [8] Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021
    Wang, YanFeng
    Cui, Chanjuan
    Ren, Xiayang
    Dong, Xinran
    Cui, Wei
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [9] Drug-associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database
    Konstantinov, Konstantin
    Dolladille, Charles
    Gillet, Benjamin
    Alexandre, Joachim
    Aouba, Achille
    Deshayes, Samuel
    Repesse, Yohann
    HAEMOPHILIA, 2023, 29 (01) : 186 - 192
  • [10] Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
    Li, Zhaohui
    Zhou, Zixiang
    Zhang, Nan
    Tian, Binhe
    Chen, Xiangqi
    Zhao, Haitao
    Wang, Hanping
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 74 (01)